Biovista's repositioning programs leverage the company's technology platform to identify suitable drugs and reposition them in isolation or in combination with other drugs to therapeutic areas that are currently not covered by existing products.

By selecting drugs that already satisfy basic toxicity, ADME and related criteria, Biovista is able to deliver significant value at reduced cost and in dramatically shorter time frames than is normally the case.

We have initiated our own drug repositioning efforts in several conditions, where the drugs we profile and screen meet two major criteria:

• they display significant biological plausibility as potential therapies for the new indications and 
• there is no prior art in the patent or scientific literature linking them to the new indications.  In addition, we screen for at least equivalent efficacy with current standards of treatment, and with equal or lower risk profiles.

Using the above criteria, Biovista's current pipeline includes:

 

Eye Disorders (Macular Degeneration, Glaucoma, Diabetic Retinopathy	8 drugs
Diabetes/Obesity	4 drugs (RNAi class)
CNS	12 drugs
Oncology	A number of drugs in pancreatic and other cancers
Other Diseases	Auto-immune and infectious diseases (in process)
Drugs coming off patent	28 drugs (major Pharma drugs losing exclusivity in the period ’08-’12), including five Pfizer drugs, six Novartis drugs, and ten Roche drugs to date

For more information on Biovista's Pipeline, please contact us at info@biovista.com